Affiliation: University of Rochester
- The potential of targeting malignant stem cells as a treatment for leukemiaCraig T Jordan
University of Rochester School of Medicine, 601 Elmwood Ave, Box 703 Rochester, NY 14642, USA
Future Oncol 1:205-7. 2005..This perspective article summarizes recent findings in the leukemia stem cell field and discusses new directions for therapy...
- Cancer stem cellsCraig T Jordan
James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
N Engl J Med 355:1253-61. 2006
- Can we finally target the leukemic stem cells?Craig T Jordan
James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
Best Pract Res Clin Haematol 21:615-20. 2008..Parameters are suggested here to help identify and quantitate leukemic stem cells in the clinical context...
- Cancer stem cell biology: from leukemia to solid tumorsCraig T Jordan
Division of Hematology Oncology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 703, Rochester, New York 14642, USA
Curr Opin Cell Biol 16:708-12. 2004..Hence, a detailed understanding of stem cells and how they mediate tumor pathogenesis will be critical in developing more effective cancer therapies...
- Cancer stem cells: controversial or just misunderstood?Craig T Jordan
James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
Cell Stem Cell 4:203-5. 2009..In this commentary, underlying points of contention are described with the aim of defining focal points for discussion and future consideration...
- Mechanisms controlling pathogenesis and survival of leukemic stem cellsCraig T Jordan
Department of Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 703, NY 14642, USA
Oncogene 23:7178-87. 2004..In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells...
- Searching for leukemia stem cells--not yet the end of the road?Craig T Jordan
James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA
Cancer Cell 10:253-4. 2006..Biological features of leukemia stem cells in this system challenge previous thinking in several ways and suggest an unexpected degree of heterogeneity among stem cells in various forms of leukemia...
- The leukemic stem cellCraig T Jordan
James P Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
Best Pract Res Clin Haematol 20:13-8. 2007..This article summarizes recent findings in the leukemic stem cell field and discusses new directions for therapy...
- Targeting myeloid leukemia stem cellsCraig T Jordan
Departments of Medicine and Biomedical Genetics and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
Sci Transl Med 2:31ps21. 2010..Here the current understanding of the LSC phenotype is described, and the potential application of antibody-based treatment regimens is discussed...
- Modulation of cell surface protein free thiols: a potential novel mechanism of action of the sesquiterpene lactone parthenolideJolanta Skalska
James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York, United States of America
PLoS ONE 4:e8115. 2009..Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hypothesized that redox active anti-cancer agents would modulate exofacial protein thiols...
- Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression dataDuane C Hassane
James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, NY, USA
Blood 111:5654-62. 2008..These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets...
- Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Monica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4436-44. 2007..We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations...
- An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
Blood 110:4427-35. 2007..Therefore, based on the collective preclinical data, we propose that the novel compound DMAPT has the potential to target human LSCs in vivo...
- Targeting the most critical cells: approaching leukemia therapy as a problem in stem cell biologyCraig T Jordan
James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
Nat Clin Pract Oncol 2:224-5. 2005
- The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cellsYun Dai
Division of Hematology Oncology, Department of Medicine, Virginia Commonwealth University, 401 College Street, Richmond, VA 23298, USA
Br J Haematol 151:70-83. 2010..They also raise the possibility that this strategy may target leukaemic progenitor cells...
- The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cellsMonica L Guzman
University of Rochester School of Medicine, 601 Elmwood Ave, Box 703, Rochester, NY 14642, USA
Blood 105:4163-9. 2005..On the basis of these findings, we propose that the activity of PTL triggers LSC-specific apoptosis and as such represents a potentially important new class of drugs for LSC-targeted therapy...
- The hematopoietic stem cell in myelodysplasiaJane L Liesveld
Leukemia Blood and Marrow Transplant Program, Rochester, NY, USA
Stem Cells 22:590-9. 2004....
- Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cellsSang Woo Kim
Department of Biomedical Genetics, University of Rochester Medical Center, Rochester, NY 14642, USA
Blood 111:1644-53. 2008..Together, these results indicate that PKK plays a pivotal role in the survival of human DLBCL cells and represents a potential target for DLBCL therapy...
- Leukemia stem cells in a genetically defined murine model of blast-crisis CMLSarah J Neering
James P Wilmot Cancer Center, University of Rochester Medical Center, NY 14642, USA
Blood 110:2578-85. 2007..Taken together, the system provides a powerful means by which the in vivo behavior of LSCs versus HSCs can be characterized and candidate treatment regimens can be optimized for maximal specificity toward primitive leukemia cells...
- A novel in vitro assay of tumor-initiating cells in xenograft prostate tumorsChristopher R Silvers
Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
Prostate 70:1379-87. 2010..In order to help circumvent this challenge, we sought to develop an in vitro assay of human prostate cancer initiation employing a prostate-associated mesenchymal feeder layer...
- In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cellsBenjamin J Frisch
Endocrine Division, University of Rochester School of Medicine, Rochester, NY 14642, USA
Blood 114:4054-63. 2009..These novel effects of PGE(2) could be exploited clinically to increase donor ST-HSCs, which are highly proliferative and could accelerate hematopoietic recovery after stem cell transplantation...
- The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF genePin Yi Wang
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, NY, USA
Blood 112:4184-92. 2008....
- High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cellsFaith M Young
Department of Medicine, University of Rochester, Rochester, New York, USA
Biol Blood Marrow Transplant 14:622-30. 2008..Thus, ALLs with INK4A/ARF or bcr/abl mutations are not intrinsically resistant to allogeneic T cell responses, suggesting that active immunotherapies against mHA have the potential to control such acute lymphoblastic leukemias...
- Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cellsJonathan M Weber
Endocrine Division, Department of Medicine, University of Rochester School of Medicine, 601 Elmwood Avenue Box 693 Rochester, NY 14642, USA
Bone 39:485-93. 2006....
- Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biologyMonica L Guzman
James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
Cancer Cell 15:252-4. 2009..In the current issue of Cancer Cell, a study by Santaguida et al. provides new insights into JunB's function and the genesis of myeloid disease...
- Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemiasShimei Gong
Department of Pediatrics, University of Kentucky, Lexington, KY 40536, USA
Exp Hematol 30:1162-9. 2002..We sought to identify OCT genes preferentially expressed in hematopoietic cells...
- Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered miceMeredith A Bostrom
Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY, USA
Arterioscler Thromb Vasc Biol 27:600-6. 2007..However, there is no direct evidence that this enzyme promotes atherogenic processes in vivo...
- Feverfew: weeding out the root of leukaemiaMonica L Guzman
Expert Opin Biol Ther 5:1147-52. 2005..Thus, this naturally occurring agent may provide new avenues of investigation for the treatment of leukaemia. In this article, characteristics of parthenolide are reviewed...
- Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levelsIvan Topisirovic
Institute for Research in Immunovirology and Cancer, University of Montreal, Montreal, Quebec H3T 1J4, Canada
Mol Cell Biol 25:1100-12. 2005....
- A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapyCraig T Jordan
Leuk Res 28:1121-2. 2004
- Preferential induction of apoptosis for primary human leukemic stem cellsMonica L Guzman
Blood and Marrow Transplant Program, Markey Cancer Center, Division of HematologyOncology, University of Kentucky Medical Center, Lexington, KY 40536 0093 USA
Proc Natl Acad Sci U S A 99:16220-5. 2002..Further, the data begin to elucidate the molecular mechanisms that underlie LSC-specific apoptosis and suggest new directions for AML therapy...
- Considerations for targeting malignant stem cells in leukemiaMonica L Guzman
Blood and Marrow Transplant Program, Markey Cancer Center, Division of Hematology Oncology, University of Kentucky Medical Center, Lexington, Kentucky, USA
Cancer Control 11:97-104. 2004..Like normal stem cells, these leukemic stem cells (LSCs) are able to self-renew, differentiate, and proliferate extensively. Evidence suggests that LSCs are critical for the initiation and perpetuation of leukemic disease...
- Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latencyFelicia D Goodrum
Department of Molecular Biology, Princeton University, Princeton, NJ 80544, USA
Proc Natl Acad Sci U S A 99:16255-60. 2002..Some of these expressed viral genes may function in latency and are targets for further analysis. Altered gene expression in hematopoietic progenitors may be indicative of the nature and outcome of HCMV infection...
- Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesisIvan Topisirovic
Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York University, One Gustave Levy Place, New York, NY 10029, USA
Mol Cell Biol 23:8992-9002. 2003..Thus, our findings indicate that this nuclear function of eIF4E can contribute to leukemogenesis by promoting growth and by impeding differentiation...
- Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulationsFelicia Goodrum
Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
Blood 104:687-95. 2004....
- The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic targetSaman Hewamana
Department of Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
Blood 111:4681-9. 2008..001, r(2) = 0.3), implicating Rel A in fludarabine resistance. Taken together, these data indicate that Rel A represents an excellent therapeutic target for this incurable disease...
- Cellular and Molecular Studies of Leukemic Stem CellssCraig Jordan; Fiscal Year: 2006..Collectively, these efforts will advance our understanding of basic mechanisms that underlie leukemic transformation and will improve strategies for the preferential ablation of LSCs. ..
- Selective in vivo Ablation of Leukemia Stem CellsCraig Jordan; Fiscal Year: 2007..Collectively, the proposed studies will provide a detailed evaluation of how therapeutic agents impact the growth and survival of LSC in vivo. ..
- Amnis ImageStream Flow CytometerCraig Jordan; Fiscal Year: 2007..Taken together, the unique capabilities of the ImageStream system will therefore serve to strongly benefit a wide range of research activities. ..
- Selective in vivo Ablation of Leukemia Stem CellsCraig Jordan; Fiscal Year: 2009..Collectively, the proposed studies will provide a detailed evaluation of how therapeutic agents impact the growth and survival of LSC in vivo. ..